PEN

In a comparison of two medical instruments sector stocks, Integra LifeSciences (IART) emerges as the better value opportunity for investors compared to Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.62 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.18 and Value grade of D. IART's superior valuation metrics and improving earnings outlook make it the more attractive choice for value investors.

A comparison of two medical instruments companies reveals that Integra LifeSciences (IART) presents a more attractive value opportunity than Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.61 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.35 and Value grade of D. IART's stronger earnings estimate revisions and superior valuation metrics make it the preferred choice for value investors.